Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

University Health Network, Toronto

Status and phase

Completed

Phase 2

Phase 1

Conditions

Oral Cavity Cancer

Treatments

Drug: PF-00299804

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01116843

WS590266

Details and patient eligibility

About

The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.

Full description

This is a single-center, randomized, double-blinded, biomarker driven, preoperative window of opportunity study with a pharmacodynamic primary endpoint. Patients with resectable, histologically confirmed OCC for whom surgical treatment is planned as definitive management, will be randomized 2:1 to receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days or to Matching Placebo for 7-11 days depending on surgery schedule. The target is a total of 8 days of treatment but with a minimum of 7 and a maximum of 11 dosing days. All patients will receive surgery as per standard of care without delay. Biomarkers from the surgical specimen and baseline tumor biopsy or consent to provide a tumor block from existing primary diagnostic tumor biopsy completed within 90 days will be evaluated for primary and secondary pharmacodynamic endpoints.

Enrollment

13 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed, voluntary informed consent provided
Willing and able to comply with scheduled visits, treatment plan, tests, other study procedures
Patient must be diagnosed with histologically confirmed oral cavity squamous cell carcinoma (OCC) (lip, floor of mouth, anterior 2/3 tongue, buccal mucosa, upper and lower gingiva, hard palate and retromolar trigone) considered resectable (T1-4a, N0-2, M0; (without distant metastases)) for whom surgical resection of tumor is planned. Patients with distant metastatic disease or diagnosis of SCCHN may not be enrolled
Must be able to provide a fresh tumor biopsy prior to randomization for histopathological and biomarker evaluation. No anti-neoplastic treatment allowed between obtaining baseline tumor specimen and randomization. Patients who decline an in-house fresh pre-treatment tumor biopsy must give consent to provide a tumor block from an existing diagnostic primary tumor biopsy completed within 90 days of enrolment
Prior treatment with agents targeted to epidermal growth factor receptor is not allowed.
No prior chemotherapy or radiotherapy (to primary site/nodes).
Patient must not have received prior anti-neoplastic treatment within past 2 years
Any treatment-related acute toxicity, including laboratory abnormalities, must have recovered to CTCAE Grade 1 (v.4.0) or baseline, except toxicity not considered a safety risk.
ECOG performance status of 0-2.
Patient must have adequate organ function as determined by the following criteria:
Serum creatinine ≤ 1.5 ULN or a calculated creatinine clearance of ≥ 50 mL/min
Absolute neutrophil count ≥ 1.5 x 109/L
Leukocytes > 3.0 x 109/L
Hemoglobin > 80 g/L
Platelets > 100 x 109/L
Total bilirubin < ULN
AST (SGOT) and ALT (SGPT) < 2.5 x ULN
12-Lead ECG with normal tracing, or clinically non-significant changes that do not require medical intervention
QTc interval < 470 msec, and without history of Torsades de Pointes or other symptomatic QTc abnormality
A normal LVEF of >50% as measured by ECHO or MUGA within 4 weeks prior to start of study treatment will be required for all patients

Exclusion criteria

Patients who require segmental mandibulectomy for surgical resection of oral cavity tumor will not be enrolled
Primary site of head and neck carcinoma in nasopharynx, skin, or unknown
Prior or concurrent radiation therapy to tumor at site of planned resection
Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of PF-00299804
Requirement for treatment with drugs that are highly dependent on CYP2D6 for metabolism since PF-00299804 is a potent CYP2D6 inhibitor in in vitro assays
Patients currently taking drugs that have a risk of causing Torsades de Pointes
Any acute or chronic medical, psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or trial drug administration or could interfere with interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry in the trial
Other serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment as determined by investigator
Dementia or significantly altered mental status that would limit the ability to obtain informed consent and compliance with the requirements of this protocol
Patients breastfeeding or pregnant are excluded. All female patients with reproductive potential must have a negative pregnancy test within 72 hours prior to treatment.
Patients of reproductive potential or their partners must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter.
Current enrollment in another therapeutic clinical trial
Inability/lack of willingness to comply with visits, treatment plans, protocol assessments or laboratory tests